View Older Stories View More Recent Stories

Sep 14, 2016 07:30AM Novartis survey published in The Breast Journal reveals major gaps in treatment discussions between metastatic breast cancer patients and doctors
Aug 3, 2016 07:08AM Novartis' (NVS) LEE011 Receives FDA Breakthrough Therapy Designation in for HR+/HER2- Advanced Breast Cancer
Aug 3, 2016 07:00AM Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Jul 7, 2016 04:41PM Novartis (NVS) Receives FDA Approval for Expanded Xolair Age Range Usage
Jul 7, 2016 04:40PM Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
Jul 5, 2016 12:11PM Streetinsider.com's Hot Lunchtime Reads 7/5: (TWTR) (TSLA) (COST) (NVS)
Jun 29, 2016 05:15PM Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
Jun 22, 2016 11:35AM Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
Jun 6, 2016 02:40PM Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Jun 4, 2016 04:05PM Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
Jun 3, 2016 08:00AM Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
Jun 2, 2016 04:18PM Novartis (NVS) Enters co-Promotion Agreement with Eisai for Lenvima Combo in RCC
Jun 2, 2016 04:17PM Novartis announces US collaboration to co-promote Lenvima® in combination with everolimus for advanced renal cell carcinoma (RCC)
May 18, 2016 05:13PM Novartis (NVS) to Present Data in Hematologic and Solid Tumor Cancers at ASCO
May 18, 2016 05:09PM Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
Apr 7, 2016 09:01AM Ligand Pharma (LGND) Announces EC Approval of Revolade as Chronic ITP Treatment in Certain Patients
Apr 6, 2016 07:31AM Incyte (INCY) Acquires Jakafi Commercialization, Development Rights from Lilly (LLY)
Apr 3, 2016 12:22PM Novartis (NVS) Annoucnes New, Positive Data for Entresto in Heart Failure Patients with Reduced HFrEF
Apr 2, 2016 11:03AM New analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior
Feb 26, 2016 03:43PM FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
Feb 19, 2016 07:16AM Novartis (NVS) PKC412 Receives FDA Breakthrough Therapy Designation in FLT3+ AML
Feb 19, 2016 07:15AM Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
Feb 8, 2016 09:43AM Cigna Corp. (CI), Novartis (NVS) Enter Outcomes-Based Contract for Entresto
Jan 25, 2016 04:30PM Novartis teams up with Pro Football Hall of Famer Troy Aikman on advanced melanoma educational and community support program
Jan 15, 2016 05:47PM Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Jan 5, 2016 03:36PM Qualcomm (QCOM), Novartis (NVS) to Expand Collaboration for COPD Therapy
Dec 23, 2015 05:07PM Novartis (NVS) Announces Publication of Cosentyx MEASURE 1, 2 Study Data in NEJM
Dec 23, 2015 05:04PM Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
Dec 7, 2015 03:03PM Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
Dec 7, 2015 12:51PM Sandoz Canada launches two easy-to-use products: Salinex(R) Seawater nasal spray for daily care and Ezeva(TM) zinc oxide cream
Dec 7, 2015 12:51PM Sandoz Canada launches two easy-to-use products: Salinex(R) Seawater nasal spray for daily care and Ezeva(TM) zinc oxide cream
Dec 7, 2015 06:26AM Novartis (NVS) Presents Updated Data from CTL019 in r/r NHL at ASH
Dec 6, 2015 11:15AM Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
Dec 6, 2015 07:46AM Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Dec 2, 2015 07:54PM Sandoz Canada Launches a New Concentration of (T/C)Lorazepam Injection USP
Dec 2, 2015 07:54PM Sandoz Canada Launches a New Concentration of (T/C)Lorazepam Injection USP
Nov 30, 2015 07:15AM Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
Nov 20, 2015 05:14PM Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data
Nov 10, 2015 05:30PM Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
Nov 7, 2015 07:37PM Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
Nov 7, 2015 07:37PM Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
Oct 29, 2015 04:50PM FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
Oct 26, 2015 02:16PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
Oct 21, 2015 09:27AM Pre-Open Stock Movers 10/21: (KLAC) (ISRG) (SNDK) Higher; (SNTA) (VMW) (TWTR) Lower (more...)
Oct 20, 2015 08:00AM Science 37 Secures $6.5M Series A Funding To Accelerate Clinical Trial Research
Oct 14, 2015 01:28PM Sandoz Canada launches new multi-platform application to show real-time availability of its injectable medicines
Oct 14, 2015 01:28PM Sandoz Canada launches new multi-platform application to show real-time availability of its injectable medicines
Oct 7, 2015 04:41PM Sandoz Canada launches PrSandoz(R) Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence
Oct 7, 2015 04:41PM Sandoz Canada launches PrSandoz(R) Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence
Sep 30, 2015 05:04PM Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
View More Recent Stories View Older Stories